Karyopharm Therapeutics Inc

CUSIP 48576UAA4NOTE 3.000%10/1KPTIQ3 2025

Karyopharm Therapeutics Inc — Owners — 13D/13G Beneficial Ownership · FBInvestor

13D / 13G Filings

Schedule 13D/13G on record

Beneficial Filers

Distinct reporting persons

Largest Stake

—

Max % of class reported

Institutional Holders

13F filers (latest quarter)

Schedule 13D (activist) & 13G (passive) 5%+ ownership filings

No 13D/13G filings on record yet

Schedule 13D/13G beneficial-ownership filings from 2020–present are ingested from SEC EDGAR. Coverage expands as the backfill and daily crawler run.

Largest reported positions · latest quarter

#	Fund	Shares	Value
1	Exome Asset Management LLC	2.00M	$1.63M
2	Blb&B Advisors, LLC	75.0K	$60.5K